Cardio-Oncology

A thorough understanding of cardio-oncology is very essential for the effective treatment of cancer patients. Virtually all antineoplastic agents are related with cardiotoxicity. All patients who are being considered for chemotherapy, particularly the individuals who have earlier history of heart sickness ought to experience point by point cardiovascular assessment to advance the treatment. Sequential examination of left ventricular systolic function and cardiac biomarkers might also be considered in the selected populations of patient. Cardio-toxic effects of chemotherapy can be decreased by the frequent use of angiotensin-converting inhibitors of enzyme, angiotensin receptor blockers, or beta-blockers. Antiplatelet or anticoagulation therapy may be taken in patients with a potential hyper-coagulable state related with chemotherapy or malignant growth.

  • Track 1-1 Vascular toxicities
  • Track 2-2 Advanced cancer therapy
  • Track 3-3 Heart malignancy
  • Track 4-4 Intra-cardiac tumor
  • Track 5-5 Cardiomyopathy
  • Track 6-6 HER2-directed therapy
  • Track 7-7 Chemotherapy-related cardiac dysfunctions
  • Track 8-8 Cardio-oncology programs

Related Conference of Cardiology